MGP
ALNY icon

Metis Global Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Metis Global Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Sell
4,009
-40
-1% -$12.1K 0.03% 404
2026
Q1 		$1.34M Sell
4,049
-136
-3% -$46.3K 0.03% 375
2025
Q4 		$1.66M Sell
4,185
-126
-3% -$55.8K 0.04% 356
2025
Q3 		$1.97M Sell
4,311
-326
-7% -$133K 0.05% 329
2025
Q2 		$1.51M Sell
4,637
-929
-17% -$257K 0.04% 371
2025
Q1 		$1.5M Buy
5,566
+839
+18% +$216K 0.04% 371
2024
Q4 		$1.11M Buy
4,727
+347
+8% +$91.3K 0.03% 413
2024
Q3 		$1.2M Buy
4,380
+1,405
+47% +$366K 0.04% 404
2024
Q2 		$723K Buy
2,975
+35
+1% +$5.53K 0.02% 470
2024
Q1 		$439K Sell
2,940
-1,442
-33% -$241K 0.02% 585
2023
Q4 		$839K Buy
4,382
+94
+2% +$16K 0.03% 436
2023
Q3 		$759K Buy
4,288
+342
+9% +$65.3K 0.04% 440
2023
Q2 		$750K Buy
3,946
+300
+8% +$59.5K 0.04% 426
2023
Q1 		$730K Buy
3,646
+1,144
+46% +$240K 0.05% 400
2022
Q4 		$595K Buy
2,502
+1,157
+86% +$247K 0.05% 388
2022
Q3 		$269K Buy
+1,345
New +$257K 0.04% 445

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Metis Global Partners's ALNY Position: Q2 2026 in Review

Metis Global Partners reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.99% in Q2 2026, selling an estimated $12.1K and leaving 4,009 shares worth $1.21M. The position accounts for 0.03% of the portfolio, ranked #404.

Metis Global Partners first reported a position in ALNY in Q3 2022 and has held it in 16 quarters since. The position peaked at $1.97M in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Metis Global Partners held 4,009 shares of Alnylam Pharmaceuticals worth $1.21M as of Q2 2026.
  • Metis Global Partners sold 40 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $12.1K.
  • Alnylam Pharmaceuticals made up 0.03% of Metis Global Partners's portfolio in Q2 2026, its #404 holding.
  • Metis Global Partners first reported a position in Alnylam Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • Metis Global Partners's Alnylam Pharmaceuticals position peaked at $1.97M in Q3 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Metis Global Partners's 13F filing for Q2 2026, filed 10 Aug 2026.